Ashwagandha

For the right person, yes. The evidence is unusually strong for an herbal supplement. Akhgarjand 2022 meta-analysis (12 RCTs, n=1,002) found anxiety SMD -0.75 and cortisol SMD -0.69 . Moderate-to-large effect sizes that compare favorably to SSRIs in anxiety meta-analyses (d 0.3-0.5). Cortisol reduction of 23-28% is replicated across three independent RCTs. Testosterone +14.7% in stressed middle-aged men (Lopresti 2019). The primary caveat: most trials are industry-funded by the extract manufacturers (Ixoreal for KSM-66, Natreon for Sensoril). Partial independent replication exists. Three millennia of Ayurvedic use corroborate the stress, fatigue, and vitality indications. Worth trying for chronically stressed adults; lower expected benefit for those with low baseline stress.

Three extracts, different plant parts, different effects. KSM-66 (Ixoreal, root-only, >= 5% withanolides) has the broadest clinical evidence base covering stress, testosterone, cognition, sleep, and athletic performance. More stimulating or neutral profile; appropriate for morning dosing. Sensoril (Natreon, root + leaf, >= 10% withanolides + oligosaccharides) includes leaf-derived triethylene glycol, which has GABAergic sleep-promoting and sedating properties; the preferred extract for sleep-onset and high-anxiety applications, taken in the evening. Shoden (Arjuna Natural, 35% withanolide glycosides) is the highest-concentration commercial extract at 60-120 mg doses; emerging evidence in sleep (Deshpande 2020) and VO2max (Perez-Gomez 2020) but a thin overall trial base. The leaf-containing extracts (Sensoril, Shoden) are more thyroid-stimulating than KSM-66; root-only is the safer default for anyone with thyroid concerns. Default recommendation: KSM-66 600 mg/day for most goals; Sensoril 250 mg PM specifically for sleep.

Real but context-dependent. Lopresti 2019 (KSM-66 600 mg/day, 57 men aged 40-70, 8 weeks): testosterone +14.7% vs +2.1% placebo, with DHEA-S +18% and cortisol -11%. The effect was concentrated in men with below-median baseline testosterone. Wankhede 2015 (resistance-trained men): +40 ng/dL absolute increase alongside training. Mechanism: cortisol suppression disinhibits LH pulsatility (cortisol directly inhibits GnRH and LH), allowing testosterone recovery. There may also be direct Leydig cell stimulation by withanolides and inhibition of aromatase. The community reality check: the 14.7% figure applies to stressed, suboptimal-T men in their 40s-70s. Men with high-normal testosterone (>700 ng/dL) and low chronic stress see minimal response. This is not a TRT replacement. If your T is crashed from chronic stress, fixing cortisol will help. If your T is low from primary hypogonadism or lifestyle issues, ashwagandha will not meaningfully compensate.

There is a documented signal you should know about. The NIH LiverTox database assigns ashwagandha a Likelihood Score B (probable cause) for idiosyncratic drug-induced liver injury. The Bjornsson 2020 Iceland case series (PMID 29742390) was the first systematic documentation: cholestatic pattern, typically onset 2 weeks to 3 months, resolving within 4-12 weeks of discontinuation. Approximately 20-35 published cases globally through 2024 . A low absolute number relative to the hundreds of millions of supplement doses consumed, but still a real signal. The pattern is idiosyncratic: no predictable dose-response has been established, meaning you cannot assume a lower dose is safe. Stop immediately if you develop jaundice, dark urine, right upper quadrant pain, or unusual fatigue. People with existing liver disease should avoid ashwagandha or use only under hepatologist supervision with regular liver function monitoring. This risk does not make the supplement categorically dangerous for healthy adults, but it requires honest disclosure.

Yes, at excessive doses or extended continuous use, this is a documented and recurring real-world complaint. The pattern is consistent across r/Nootropics, r/Supplements, and Longecity: users taking above 600 mg/day or using continuously for 3+ months describe emotional flatness, loss of motivation, reduced competitive drive, and apathy. The anxiolytic effect continues but extends into blunted emotional reactivity. Proposed mechanism: cortisol is not purely a stress hormone. Basal cortisol drives motivation, reward anticipation, and emotional arousal. Chronic over-suppression of cortisol flattens these positive functions alongside the negative ones. Risk factors: doses above 600 mg/day (particularly 1,200 mg/day or higher), no cycling break, already-low baseline cortisol (burnout state), and stacking with other cortisol-lowering agents. Mitigation: cap dose at 300-600 mg/day; cycle 8 weeks on / 2-4 weeks off; take in the evening to limit daytime blunting; stop entirely if drive and passion are affected, typically washing out within 1-2 weeks after cessation.

It depends entirely on your thyroid status. For subclinical hypothyroid: Sharma 2018 (PMID 29942054) showed TSH normalization and dramatic T3/T4 elevation (T3 +41.5 ng/dL, T4 +8.5 mcg/dL) in a 600 mg/day KSM-66 RCT over 8 weeks. The effect rivals low-dose levothyroxine for TSH normalization. For hyperthyroidism or Graves' disease: this same thyroid-stimulating mechanism is a hard contraindication. Cases of thyroid storm following ashwagandha supplementation have been published (PMID 33680375). This is not theoretical. For Hashimoto's with hypothyroid-dominant status: potentially beneficial, but monitor TSH/T3/T4 quarterly. Root-only extract (KSM-66) is considered lower risk than leaf-containing extracts (Sensoril, Shoden) because leaf-derived withaferin A appears to drive more of the thyroid stimulation. Anyone currently taking thyroid medication (levothyroxine, methimazole, propylthiouracil) needs physician oversight before adding ashwagandha due to drug interaction.

Endpoint-dependent and faster than most adaptogens. The GABAergic mechanism (triethylene glycol, especially in Sensoril) acts within days, producing anxiolytic and sleep-onset effects in the first 1-2 weeks. This is why ashwagandha is one of the few adaptogens where users report noticeable change quickly. Cortisol reduction is measurable at 4-8 weeks across most RCTs. Testosterone elevation requires 8 weeks minimum for significant change; thyroid normalization similarly at 8 weeks (Sharma 2018). Strength and lean mass endpoints (Wankhede 2015) were measured at 8 weeks. VO2max improvement (Choudhary 2015) at 8 weeks. Full adaptogenic HPA normalization is considered to take 8-12 weeks of consistent use, consistent with most trial durations. After stopping, benefits typically fade within 2-4 weeks for sleep and anxiety, and within 4-8 weeks for cortisol and testosterone, with full washout in under 8 weeks. No permanent effects.

The community consensus is strongly pro-cycling, though no RCT has directly compared cycling vs continuous protocols. The typical recommendation is 8 weeks on / 2-4 weeks off. The rationale: many experienced users report diminishing anxiolytic and sleep benefits after 3+ months of continuous use; cycling appears to reset HPA sensitivity with effects renewing strongly on restart. The mood-blunting concern (see above) is also managed by cycling, since cortisol over-suppression requires extended continuous exposure to develop. The dissenting view: some functional medicine practitioners and continuous users report stable benefits year-round without cycling, arguing tolerance mechanisms have not been demonstrated. Given the mood-blunting signal at continuous high doses and the absence of RCT data supporting continuous >12-week safety beyond a single 6-month Ixoreal-funded trial (Gopukumar 2021), cycling is the more conservative approach. A 5-days-on / 2-days-off pattern is also used as a lighter alternative to full breaks.